Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:19 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 542934 | NSE: CBPL

Chandra Bhagat Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹30.83Fairly Valued by 3.66%vs CMP ₹32.00

P/E (38.9) × ROE (2.4%) × BV (₹40.30) × DY (2.00%)

₹28.10Overvalued by 12.19%vs CMP ₹32.00
MoS: -13.9% (Negative)Confidence: 38/100 (Low)Models: 2 Under, 1 Fair, 3 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹29.3634%Fair (-8.3%)
Graham NumberEarnings₹27.4325%Over (-14.3%)
Net Asset ValueAssets₹40.3911%Under (+26.2%)
Earnings YieldEarnings₹8.3011%Over (-74.1%)
ROCE CapitalReturns₹11.1211%Over (-65.3%)
Revenue MultipleRevenue₹57.578%Under (+79.9%)
Consensus (6 models)₹28.10100%Overvalued
Key Drivers: ROE 2.4% is below cost of equity. | Wide model spread (₹8–₹58) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -4.8%

*Investments are subject to market risks

Investment Snapshot

45
Chandra Bhagat Pharma Ltd scores 45/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health54/100 · Moderate
ROCE 6.0% WeakROE 2.4% WeakD/E 0.96 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changeDII holding down 0.89% MF sellingPromoter increased by 0.99% Positive
Earnings Quality40/100 · Moderate
OPM contracting (3% → -2%) Declining
Quarterly Momentum53/100 · Moderate
Revenue (4Q): -26% YoY DecliningProfit (4Q): +16% YoY PositiveOPM: 6.5% (up 10.7% YoY) Margin expansion
Industry Rank20/100 · Weak
P/E 38.9 vs industry 53.8 In-lineROCE 6.0% vs industry 16.4% Below peersROE 2.4% vs industry 15.2% Below peers3Y sales CAGR: -3% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:19 am

Market Cap 24.1 Cr.
Current Price 32.0
Intrinsic Value₹28.10
High / Low 61.5/30.0
Stock P/E38.9
Book Value 40.3
Dividend Yield0.00 %
ROCE6.00 %
ROE2.41 %
Face Value 10.0
PEG Ratio-8.15

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Chandra Bhagat Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Chandra Bhagat Pharma Ltd 24.1 Cr. 32.0 61.5/30.038.9 40.30.00 %6.00 %2.41 % 10.0
Glaxosmithkline Pharmaceuticals Ltd 39,458 Cr. 2,329 3,516/2,21839.2 1011.80 %63.2 %46.9 % 10.0
Cohance Lifesciences Ltd 11,934 Cr. 312 1,250/26739.7 99.00.00 %14.9 %12.7 % 1.00
Abbott India Ltd 56,291 Cr. 26,490 37,000/25,35036.9 1,8881.79 %46.2 %35.7 % 10.0
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Chandra Bhagat Pharma Ltd

Quarterly Result

MetricSep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 22.3648.3343.1550.9344.2775.40119.26102.1164.9221.8025.55
Expenses 20.7146.6741.5349.8743.2473.60124.26104.1566.1122.0623.88
Operating Profit 1.651.661.621.061.031.80-5.00-2.04-1.19-0.261.67
OPM % 7.38%3.43%3.75%2.08%2.33%2.39%-4.19%-2.00%-1.83%-1.19%6.54%
Other Income 0.020.460.471.150.600.197.014.323.072.450.34
Interest 1.621.861.451.631.041.150.660.730.851.100.81
Depreciation 0.010.020.060.060.050.220.430.210.410.540.61
Profit before tax 0.040.240.580.520.540.620.921.340.620.550.59
Tax % 25.00%33.33%24.14%30.77%31.48%14.52%31.52%33.58%-11.29%69.09%22.03%
Net Profit 0.030.160.430.360.370.540.630.900.680.170.45
EPS in Rs 0.040.210.570.480.490.720.831.190.900.230.60

Last Updated: December 27, 2025, 2:34 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 3:59 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 48.0161.1379.8489.7997.06106.2893.9770.7094.04119.67221.3786.7247.35
Expenses 46.1858.1376.4285.4192.47101.6990.8567.0291.20116.33228.4188.1445.94
Operating Profit 1.833.003.424.384.594.593.123.682.843.34-7.04-1.421.41
OPM % 3.81%4.91%4.28%4.88%4.73%4.32%3.32%5.21%3.02%2.79%-3.18%-1.64%2.98%
Other Income 0.640.310.380.490.670.440.440.481.620.2911.335.492.79
Interest 1.882.352.833.813.674.093.113.763.242.201.391.951.91
Depreciation 0.170.260.240.140.060.050.030.120.120.270.640.951.15
Profit before tax 0.420.700.730.921.530.890.420.281.101.162.261.171.14
Tax % 16.67%38.57%50.68%27.17%32.68%22.47%26.19%32.14%27.27%21.55%32.74%26.50%
Net Profit 0.350.430.350.661.030.690.310.190.800.911.530.860.62
EPS in Rs 8.3710.298.3715.7924.6410.290.410.251.061.212.031.140.83
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)22.86%-18.60%88.57%56.06%-33.01%-55.07%-38.71%321.05%13.75%68.13%-43.79%
Change in YoY Net Profit Growth (%)0.00%-41.46%107.18%-32.51%-89.07%-22.06%16.36%359.76%-307.30%54.38%-111.92%

Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:-2%
3 Years:-3%
TTM:-61%
Compounded Profit Growth
10 Years:7%
5 Years:23%
3 Years:2%
TTM:-44%
Stock Price CAGR
10 Years:%
5 Years:4%
3 Years:-23%
1 Year:-39%
Return on Equity
10 Years:4%
5 Years:3%
3 Years:4%
Last Year:3%

Last Updated: September 5, 2025, 2:51 pm

Balance Sheet

Last Updated: December 4, 2025, 2:36 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.420.420.420.420.420.677.557.557.557.557.557.557.55
Reserves 5.555.986.336.998.0313.7818.1418.3319.1319.9321.4622.4222.87
Borrowings 18.5827.5027.8322.0821.7531.2229.9327.0721.1118.9416.4320.8621.11
Other Liabilities 7.078.399.9126.4027.8637.1919.1218.8324.6814.1656.3750.7036.67
Total Liabilities 31.6242.2944.4955.8958.0682.8674.7471.7872.4760.58101.81101.5388.20
Fixed Assets 1.020.870.690.550.510.460.440.420.470.732.522.622.04
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments 0.000.000.004.641.054.030.750.000.220.110.130.141.19
Other Assets 30.6041.4243.8050.7056.5078.3773.5571.3671.7859.7499.1698.7784.97
Total Assets 31.6242.2944.4955.8958.0682.8674.7471.7872.4760.58101.81101.5388.20

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.000.000.00-9.03-6.184.05-7.418.3312.405.266.18-5.58
Cash from Investing Activity + 0.000.000.000.30-0.36-0.400.050.120.09-0.06-1.85-1.23
Cash from Financing Activity + 0.000.000.007.976.51-3.736.94-6.42-9.62-4.45-5.802.19
Net Cash Flow 0.000.000.00-0.75-0.02-0.08-0.432.022.860.76-1.48-4.62
Free Cash Flow 0.000.000.00-9.03-6.204.04-7.418.3112.314.893.90-6.78
CFO/OP 0%0%0%-200%-129%98%-238%229%440%164%-94%354%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-16.75-24.50-24.41-17.70-17.16-26.63-26.81-23.39-18.27-15.60-23.47-22.28

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 65.1570.9966.1579.9267.1690.3254.5079.6158.2224.9865.05151.31
Inventory Days 161.44176.71122.83132.66144.60173.53186.75214.70153.2599.5915.233.44
Days Payable 53.0143.1832.8180.6968.58117.3753.1378.5111.9810.6223.2144.58
Cash Conversion Cycle 173.59204.52156.17131.89143.18146.48188.12215.80199.49113.9557.06110.17
Working Capital Days 148.78166.47133.63124.96138.5083.39147.60177.18103.9475.0035.89115.28
ROCE %11.68%10.44%10.40%14.77%17.42%13.13%6.97%7.44%8.62%7.13%7.95%6.00%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Promoters 70.42%70.42%71.80%71.80%70.11%69.09%68.24%68.69%68.77%69.29%71.20%72.19%
FIIs 0.00%0.00%0.00%0.00%0.00%0.85%0.85%1.33%1.33%0.48%0.61%0.61%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.89%0.89%0.00%0.00%0.00%
Public 29.58%29.58%28.20%28.20%29.89%30.07%30.91%29.09%29.02%30.23%28.18%27.20%
No. of Shareholders 17815610690126126146134152315316301

Shareholding Pattern Chart

No. of Shareholders

Chandra Bhagat Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 1.142.031.201.060.25
Diluted EPS (Rs.) 1.142.031.201.060.25
Cash EPS (Rs.) 2.402.881.551.220.29
Book Value[Excl.RevalReserv]/Share (Rs.) 39.7238.4536.4235.3534.30
Book Value[Incl.RevalReserv]/Share (Rs.) 39.7238.4536.4235.3534.30
Revenue From Operations / Share (Rs.) 114.93293.40158.61124.6893.70
PBDIT / Share (Rs.) 5.395.694.795.691.05
PBIT / Share (Rs.) 4.134.844.445.531.01
PBT / Share (Rs.) 1.543.001.541.450.36
Net Profit / Share (Rs.) 1.142.031.201.050.25
PBDIT Margin (%) 4.681.933.014.561.12
PBIT Margin (%) 3.581.642.794.431.07
PBT Margin (%) 1.341.020.971.160.39
Net Profit Margin (%) 0.980.690.750.840.26
Return on Networth / Equity (%) 2.865.273.292.980.73
Return on Capital Employeed (%) 9.6411.869.9512.121.95
Return On Assets (%) 0.841.501.491.090.26
Long Term Debt / Equity (X) 0.070.040.140.200.36
Total Debt / Equity (X) 0.690.560.680.740.96
Asset Turnover Ratio (%) 0.852.731.801.300.96
Current Ratio (X) 1.411.382.191.862.13
Quick Ratio (X) 1.401.261.110.961.06
Inventory Turnover Ratio (X) 18.511.540.530.070.23
Interest Coverage Ratio (X) 2.093.091.651.401.65
Interest Coverage Ratio (Post Tax) (X) 1.442.101.411.261.39
Enterprise Value (Cr.) 59.6883.1485.6999.9252.54
EV / Net Operating Revenue (X) 0.680.370.711.060.74
EV / EBITDA (X) 14.6819.3823.7123.2666.02
MarketCap / Net Operating Revenue (X) 0.450.320.610.910.42
Price / BV (X) 1.322.472.663.221.15
Price / Net Operating Revenue (X) 0.450.320.610.910.42
EarningsYield 0.020.020.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Chandra Bhagat Pharma Ltd. is a Public Limited Listed company incorporated on 10/03/2003 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH2003PLC139534 and registration number is 139534. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 86.72 Cr. and Equity Capital is Rs. 7.55 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals323-F Bhagat Bhuvan, Dr. Ambedkar Road, Mumbai Maharashtra 400019Contact not found
Management
NamePosition Held
Mr. Hemant Chandravadan BhagatChairman & Managing Director
Mr. Pranav Hemant BhagatWhole Time Director
Ms. Prachi Pranav BhagatDirector & CFO
Mr. Ravindra Gajanan AwatiIndependent Director
Ms. Abha Praveen DoshiIndependent Director

FAQ

What is the intrinsic value of Chandra Bhagat Pharma Ltd and is it undervalued?

As of 17 April 2026, Chandra Bhagat Pharma Ltd's intrinsic value is ₹28.10, which is 12.19% lower than the current market price of ₹32.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (2.41 %), book value (₹40.3), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Chandra Bhagat Pharma Ltd?

Chandra Bhagat Pharma Ltd is trading at ₹32.00 as of 17 April 2026, with a FY2026-2027 high of ₹61.5 and low of ₹30.0. The stock is currently near its 52-week low. Market cap stands at ₹24.1 Cr..

How does Chandra Bhagat Pharma Ltd's P/E ratio compare to its industry?

Chandra Bhagat Pharma Ltd has a P/E ratio of 38.9, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Chandra Bhagat Pharma Ltd financially healthy?

Key indicators for Chandra Bhagat Pharma Ltd: ROCE of 6.00 % is on the lower side compared to the industry average of 16.35%; ROE of 2.41 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Chandra Bhagat Pharma Ltd profitable and how is the profit trend?

Chandra Bhagat Pharma Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹87 Cr. Compared to ₹1 Cr in Mar 2022, the net profit shows an improving trend.

Does Chandra Bhagat Pharma Ltd pay dividends?

Chandra Bhagat Pharma Ltd has a dividend yield of 0.00 % at the current price of ₹32.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Chandra Bhagat Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports